Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PAVmed (PAVM) Gains from Investment Securities (2022 - 2025)

Historic Gains from Investment Securities for PAVmed (PAVM) over the last 4 years, with Q3 2025 value amounting to $61146.0.

  • PAVmed's Gains from Investment Securities changed N/A to $61146.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $61146.0, marking a year-over-year change of. This contributed to the annual value of $66720.0 for FY2024, which is 7833.77% down from last year.
  • As of Q3 2025, PAVmed's Gains from Investment Securities stood at $61146.0.
  • In the past 5 years, PAVmed's Gains from Investment Securities registered a high of $2.5 million during Q2 2025, and its lowest value of $2000.0 during Q1 2025.
  • In the last 4 years, PAVmed's Gains from Investment Securities had a median value of $45073.0 in 2022 and averaged $222684.7.
  • Data for PAVmed's Gains from Investment Securities shows a peak YoY increase of 364700.24% (in 2025) and a maximum YoY decrease of 9700.24% (in 2025) over the last 5 years.
  • Over the past 4 years, PAVmed's Gains from Investment Securities (Quarter) stood at $15000.0 in 2022, then crashed by 73.33% to $4000.0 in 2023, then soared by 300.0% to $16000.0 in 2024, then skyrocketed by 282.16% to $61146.0 in 2025.
  • Its Gains from Investment Securities was $61146.0 in Q3 2025, compared to $2.5 million in Q2 2025 and $2000.0 in Q1 2025.